IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer

Tuesday, December 10, 2024 1 min read

Key Takeaway: IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer

Full Press Release Details

IDEAYA Announces First Patient In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA R pembrolizumab in Patients with Endometrial Cancer.

FDA Calendar

BPW Portfolio

Historical FDA Calendar

Market Movers

Biotech Earning Calendar

Historical PDUFA Dates

PDUFA Calendar

Conference Calendar

IPO

Catalyst Sync™

Hedge Fund Screener

Company Screener

All Stocks Holdings

Heat-Map

Inside Trades

Biotech Analyst Ratings

M&A Tracker

News

Blogs

Modality Leaderboard

Discord

User Guide

Biotech Investing 101

Recent Updates

Recently added Catalysts

Full Press Release Details